pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals patent portfolio — 16 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Indianapolis, USA
- Employees
- 17
- Programs
- 4
- Drugs
- 6
- Patents
- 16
Acadia Pharmaceuticals patents
16 pharmaceutical patents indexed for Acadia Pharmaceuticals. 0 expire within 24 months.
Acadia Pharmaceuticals has 16 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11827600
Crystalline forms of trofinetide
granted -
US 11464768
Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
granted -
US 11452721
Formulations of pimavanserin
granted -
US 11191757
Combination of pimavanserin and cytochrome P450 modulators
granted -
US 11135211
Pimavanserin for treating impulse control disorder
granted -
US 10953000
Combination of pimavanserin and cytochrome P450 modulators
granted -
US 10849891
Formulations of pimavanserin
granted -
US 10646480
Formulations of pimavanserin
granted -
US 10517860
Combination of pimavanserin and cytochrome P450 modulators
granted -
US 10449185
Formulations of pimavanserin
granted -
US 9757366
Methods for the treatment of parkinson's disease psychosis using pimavanserin
granted -
US 9446037
Methods for the treatment of parkinson's disease psychosis using pimavanserin
granted -
US 9050343
Combination of pimavanserin and risperidone for the treatment of psychosis
granted -
US 7732615
N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
granted -
US 7659285
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 7601740
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted
Frequently asked questions
How many patents does Acadia Pharmaceuticals have?
16 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Acadia Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.